10.3390/MOLECULES27010167 170 ShiX.XiangS.CaoJ.ZhuH.YangB.HeQ.et al (2019)
Comparing GLP-1 Pills and Injectable Regimens When comparing oral GLP-1 medications with injectable options, clinicians must weigh efficacy, cardiovascular data, dosing schedules, and patient lifestyle
Ivanov SD, Semenov AL, Kovanko EG, Yamshanov VA
AlphaDEX is a trademark owned by FTP and has been licensed to Nasdaq for use in the name of the Global Index
However, worth noting, Retatrutide remains a research compound only , it isnt approved for any therapeutic use, and all comparisons refer strictly to pre-clinical research findings
GLP-1 receptor agonist medications are FDA-approved for adults who meet one of the following criteria: a body mass index (BMI) of 30 or higher (classified as obesity), or a BMI of 27 or higher (overweight) combined with at least one weight-related health condition such as type 2 diabetes, high blood pressure, high cholesterol, sleep apnea, or cardiovascular disease
